12.01
-0.16(-1.31%)
Currency In USD
| Previous Close | 12.17 |
| Open | 12.17 |
| Day High | 12.39 |
| Day Low | 12.01 |
| 52-Week High | 16.5 |
| 52-Week Low | 8.06 |
| Volume | 33,494 |
| Average Volume | 55,153 |
| Market Cap | 160.55M |
| PE | -8.77 |
| EPS | -1.37 |
| Moving Average 50 Days | 10.56 |
| Moving Average 200 Days | 11.43 |
| Change | -0.16 |
If you invested $1000 in Greenwich LifeSciences, Inc. (GLSI) since IPO date, it would be worth $2,402 as of August 18, 2025 at a share price of $12.01. Whereas If you bought $1000 worth of Greenwich LifeSciences, Inc. (GLSI) shares 3 years ago, it would be worth $1,190.29 as of August 18, 2025 at a share price of $12.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
GlobeNewswire Inc.
Aug 13, 2025 10:00 AM GMT
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
GlobeNewswire Inc.
Aug 11, 2025 10:00 AM GMT
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
GlobeNewswire Inc.
Apr 02, 2025 10:00 AM GMT
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immun